Historique
Périodique
Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases
(Dépersonnalisation chronique après un usage de drogues illicites : une analyse contrôlée de 40 cas.)
Auteur(s) :
MEDFORD, N. ;
BAKER, D. ;
HUNTER, E. ;
SIERRA, M. ;
LAWRENCE, E. ;
PHILLIPS, M. L. ;
DAVID, A. S.
Année
2003
Page(s) :
1731-1736
Langue(s) :
Anglais
Refs biblio. :
26
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PSY (Psychopathologie / Psychopathology)
Note générale :
Addiction, 2003, 98, (12), 1731-1736, tabl.
Résumé :
FRANÇAIS :
Les cas étudiés proviennent de la base de données de l'Unité de recherche sur la dépersonnalisation du Maudsley Hospital de Londres. 30 hommes et 10 femmes attribuaient leurs symptômes de dépersonnalisation à un usage de drogues illicites (20 au cannabis, 4 à la MDMA, 2 au LSD et 1 à la kétamine, les autres à une polyconsommation). La comparaison avec un groupe de non-usager de drogues présentant des symptômes de dépersonnalisation, ne montre pas de différences significatives : les mécanismes neurocognitifs sont similaires entre les deux groupes cliniques.
ENGLISH:
Aims: To examine demographic and clinical features of a group of patients reporting chronic depersonalization (DP) following illicit drug use, and to assess whether depersonalization arising in these circumstances constitutes a distinct clinical syndrome. Design: Case-control comparison using self-reports, standardized questionnaires and clinical assessments in a specialized clinic. Setting: A tertiary referral depersonalization clinic and research unit affiliated to a psychiatric hospital and research centre. Participants: A total of 164 individuals with chronic DP symptoms who had been in contact with the clinic. Forty of these individuals related the onset of symptoms to an episode of illicit drug use. Measurements: A wide range of demographic and clinical variables measured using questionnaires and standardized rating scales. Findings: The drug-induced DP group were significantly younger and had a preponderance of males compared to the non-drug group. Certain clinical and phenomenological differences were found between these groups, but in general the groups are strikingly similar. This is reinforced by the fact that when the drug-induced group was compared with an age and sex-matched subset of the non-drug group, differences between groups largely disappeared. Conclusions: Drug-induced DP does not appear to represent a distinct clinical syndrome. The neurocognitive mechanisms of the genesis and maintenance of DP are likely to be similar across clinical groups, regardless of precipitants. (Author' s abstract)
Les cas étudiés proviennent de la base de données de l'Unité de recherche sur la dépersonnalisation du Maudsley Hospital de Londres. 30 hommes et 10 femmes attribuaient leurs symptômes de dépersonnalisation à un usage de drogues illicites (20 au cannabis, 4 à la MDMA, 2 au LSD et 1 à la kétamine, les autres à une polyconsommation). La comparaison avec un groupe de non-usager de drogues présentant des symptômes de dépersonnalisation, ne montre pas de différences significatives : les mécanismes neurocognitifs sont similaires entre les deux groupes cliniques.
ENGLISH:
Aims: To examine demographic and clinical features of a group of patients reporting chronic depersonalization (DP) following illicit drug use, and to assess whether depersonalization arising in these circumstances constitutes a distinct clinical syndrome. Design: Case-control comparison using self-reports, standardized questionnaires and clinical assessments in a specialized clinic. Setting: A tertiary referral depersonalization clinic and research unit affiliated to a psychiatric hospital and research centre. Participants: A total of 164 individuals with chronic DP symptoms who had been in contact with the clinic. Forty of these individuals related the onset of symptoms to an episode of illicit drug use. Measurements: A wide range of demographic and clinical variables measured using questionnaires and standardized rating scales. Findings: The drug-induced DP group were significantly younger and had a preponderance of males compared to the non-drug group. Certain clinical and phenomenological differences were found between these groups, but in general the groups are strikingly similar. This is reinforced by the fact that when the drug-induced group was compared with an age and sex-matched subset of the non-drug group, differences between groups largely disappeared. Conclusions: Drug-induced DP does not appear to represent a distinct clinical syndrome. The neurocognitive mechanisms of the genesis and maintenance of DP are likely to be similar across clinical groups, regardless of precipitants. (Author' s abstract)
Affiliation :
PO Box 68, Insitute of Psychiatry, London SE5 8AF.
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.